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Abstract
Rationale Effective functioning of the neurotransmitter sero-
tonin is important for optimal cognitive and emotional func-
tion. Dietary supplements able to increase availability to the
brain of the precursor amino acid, tryptophan (TRP), and
thereby enhance serotonin synthesis, can have measurable
impact on these psychological processes.
Objectives This study involves a randomised controlled trial
of a TRP-rich egg-white protein hydrolysate (DSM Nutrition-
al Products Ltd., Switzerland) on plasma amino acids, cogni-
tion, mood and emotional processing in older women.
Methods Following a baseline test day without treatment, 60
healthy women aged 45–65 years received drinks containing
either 2 or 4 g of TRP-rich protein hydrolysate product or
3.11 g casein hydrolysate as a control. One hour later, they
undertook a 2-h battery of cognitive and emotional tests.
Results The TRP-rich protein hydrolysate produced the ex-
pected dose-dependent increase in the ratio of plasma TRP to
competing large neutral amino acids. TRP-rich protein hydro-
lysate (2 g only) prevented both the decline in wellbeing and
increase in fatigue seen over the test session in the control
group. This treatment dose resulted in a significant shift in
emotional processing towards positive words and reduced
negative bias in assessing negative facial expressions. Effects
on cognition were small and not statistically reliable and are
not reported here. However, there was no evidence for any
adverse effects.
Conclusions Consumption of a low dose of TRP-rich protein
hydrolysate may have beneficial effects on emotional function
that could promote feelings of wellbeing, possibly conferring
resistance to deterioration in mood in healthy subjects or
depressive episodes.
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Introduction
Recent work has established a key role for central serotonin
(5-hydroxytryptamine (5-HT)) in the processing of emotion-
ally relevant stimuli, as well as in cognitive function, espe-
cially memory, attention and information processing (Riedel
et al. 2003). Thus, reduced 5-HT availability or turnover has
been associated with impaired long-term memory but im-
proved focused attention (Booij et al. 2005; Sobczak et al.
2002b); by contrast, increased 5-HT release, for example, after
loading with high doses of the precursor amino acid L-trypto-
phan (TRP) can result in reduced vigilance (Schmitt et al.
2006; Silber and Schmitt 2010).
These effects of reduced 5-HT function are thought to
underlie changes in emotional processing and cognitions as-
sociated with depression, anxiety and poor stress coping
(Robinson and Sahakian 2009); thus, antidepressants may
exert their beneficial effects by normalising deficits in central
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5-HT transmission, although the precise mechanism for this
remains elusive (Cowen 2008).
The strongest evidence for a role for functional 5-HT
deficits in depression arises from studies using amino acid
loads devoid of the precursor amino acid TRP to suppress 5-
HT synthesis (acute TRP depletion (ATD)) (Young 2013;
Young et al. 1985). This results in a substantial (e.g. >70 %)
drop in plasma TRP within 4–6 h, and can induce dysphoric
mood, especially in recovered depressives or those genetically
at risk (Silber and Schmitt 2010). Essentially, reducing TRP
access to the brain in this way tends to mimic the cognitive
biases seen in depressed populations, such as impaired mem-
ory for, or attention to, positive vs. negative information
(Mathews andMacLeod 2005). Thus, recognition of emotions
in faces can be affected by ATD: for example, recognition of
fear was reduced in women (Harmer et al. 2003). Further-
more, using asymmetry of the frontal electroencephalographic
(EEG) power spectrum, an indicator of risk of depression and
poor psychological wellbeing, Allen et al. (2009) showed that
the extent to which ATD altered the EEG asymmetry in at-risk
and healthy subjects predicted occurrence of depression in the
following 6–12 months.
Conversely, an important question is whether similar be-
haviours can be improved by increasing/facilitating entry of
TRP into the brain and thus elevating 5-HT synthesis. Indeed,
there has been long-standing clinical and research interest on
effects of oral or intravenous dosing with TRP (Fernstrom
2012). One particularly relevant finding has been the induc-
tion of a positive bias in processing of emotional faces in
women (Murphy et al. 2006). However, a complication of
oral TRP as the free amino acid is that it increases release of
several hormones including growth hormone, cortisol and
prolactin (the latter thought to indicate increased central sero-
tonin—and dopamine—activity) (Porter et al. 2003).
It has long been recognised that serotonin synthesis in the
brain can be affected by dietary manipulations that change
availability of TRP to the brain. The rationale for interest in
dietary manipulation of serotonin arises from the following
facts: (i) TRP is an essential amino acid that has to be obtained
from the diet and cannot itself be synthesised in the body; (ii)
in the synthesis of 5-HT, the rate-limiting enzyme step in-
volves conversion of TRP to 5-hydroxytryptophan (5-HTP)
by TRP hydroxylase, prior to synthesis of serotonin; and (iii)
TRP hydroxylase is not fully saturated by substrate, and so
synthesis is sensitive to substrate availability, i.e. the brain
level of TRP. Thus, increasing or decreasing TRP ingestion
could in principle raise or lower 5-HTsynthesis. However, the
situation is more complex because of a specific transport
system through the blood brain barrier (BBB) and liver me-
tabolism. To enter the brain across the BBB, TRP has to
compete for uptake not only against other amino acids, in
particular a group known as the large neutral amino acids
(LNAA), especially the branched chain amino acids, leucine,
isoleucine and valine, but also phenylalanine and tyrosine (the
precursors for catecholamine transmitter synthesis). For this
reason, the ratio of plasma or serum-free TRP/LNAA is typ-
ically thought to be the best predictor of uptake of TRP into
the brain. TRP is the scarcest amino acid in most dietary
protein, so eating a protein-rich meal normally reduces this
ratio: conversely, eating a high-carbohydrate, low-protein
meal will raise the ratio, particularly as the rise in insulin leads
to peripheral tissue uptake of the competing LNAA
(Fernstrom and Fernstrom 1995).
This mechanism has been suggested to underlie dietary
effects on mood and performance, such as calming after
high-carbohydrate meals vs. arousal after protein-rich meals
(Gibson and Green 2002; Hoyland et al. 2008). More specif-
ically, there is evidence that individuals with inherently insuf-
ficient 5-HT activity, who may be prone to neuroticism or
depression, may be most likely to benefit, in mood and cog-
nition, from a 5-HT-enhancing high-carbohydrate, low-
protein diet (Markus et al. 1998, 1999).
In recent years, a method has been developed to enhance
TRP availability to the brain, and so potentially 5-HT func-
tion, by administering TRP-rich dietary proteins: the most
published example is the whey protein α-lactalbumin. The
effects of this protein are usually compared with responses
after another protein, typically casein hydrolysate (another
milk protein), which has lower levels of TRP but greater
amounts of the competing LNAA. In addition, the proteins
have typically (though not always) been given on two occa-
sions, as drink supplements to high-carbohydrate meals
(Schmitt et al. 2005).
α-Lactalbumin has been shown to enhance (or correct)
serotonin function (indexed by prolactin release) and cogni-
tion, and to reduce cortisol release, in stress-prone (more
anxious) participants (Markus et al. 2000, 2002). Another
‘vulnerable’ group investigated is women suffering from pre-
menstrual syndrome, in whom memory may be impaired
premenstrually. α-Lactalbumin attenuated deficits in delayed
memory for abstract patterns in this group (Schmitt et al.
2005) , and in recovered depressives and healthy subjects
(Booij et al. 2006). There are also reports of increased percep-
tion of emotional faces with TRP-rich protein in women
(Attenburrow et al. 2003): however, so far, effects on emo-
tional face processing appear to be weaker or less specific than
dosing with TRP alone (Scrutton et al. 2007).
LumiVida™, a product developed by DSM Nutritional
Products Ltd., is based on a similar premise, but is an egg-
white protein hydrolysate formulation that contains fewer
competing LNAAs. LumiVida™ has recently been shown to
be more effective in raising plasma TRP/LNAA ratios than
either α-lactalbumin or TRP alone (Markus et al. 2008;
Mitchell et al. 2011). There is preliminary evidence that this
high (12 g) dose of LumiVida™ may be effective in improv-
ing mood (Markus et al. 2008) and in enhancing psychomotor
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and vigilance performance, at least in individuals more resil-
ient to stress (Markus et al. 2010).
This report concerns the acute effects of two relatively low
doses of LumiVida™ on emotional and cognitive function in
healthy middle-aged women. In selecting the doses, the inten-
tion was to detect the smallest efficacious doses for modifica-
tion of plasma TRP/LNAA ratio and behaviour. Women were
chosen because (a) they are more prone to suffer from anxiety
and depression over their lifetime than men and (b) there is
evidence that women may be more sensitive to behavioural
effects of 5-HT manipulations (Murphy et al. 2006). Older
women were also more likely to have relatively stable sex
hormone levels, thus avoiding another potential confound
(Schmitt et al. 2005). The timing of testing (1 to 3 h after the
treatment drink) was intended to follow peak increases in
plasma TRP/LNAA ratio (Collins et al. 2013; Fernstrom and
Fernstrom 1995), with the expectation of maximising any
impact of early increases in 5-HT synthesis and release on
outcome measures.
Based on the findings described above, it was hypothesised
that (a) acute treatment with LumiVida™ would cause dose-
dependent increases in plasma TRP levels and TRP/LNAA
ratio; (b) LumiVida™ would improve mood, psychological
wellbeing and emotional processing, in line with effects seen
with enhancement of serotonin function, including reducing
negative bias in face recognition and perception of emotional
stimuli; and (c) LumiVida™would improve performance, in a
dose-dependent manner, on tests of hand-eye coordination,
verbal memory, working memory, sustained attention and
driver hazard perception. Importantly, this range of tests also
allows the study to determine whether these treatments pro-




This study was double-blind, randomised and controlled with
treatment between subjects. Sixty women were randomised to
control (casein hydrolysate, 3.11 g), LumiVida™ (egg-white
protein hydrolysate, 2 g) or LumiVida™ (4 g). Prior to any
testing, randomisation was stratified within three age sub-
groups (using Excel) to ensure an even spread of ages across
treatment groups. Three participants failed to begin the study
after randomisation (personal reasons). The final sample sizes
were: control (N=19; 2 g (N=20); 4 g (N=21). Each partici-
pant received either a single dose of the egg-white protein
hydrolysate supplement, or casein hydrolysate as a protein
control, on the treatment test day. The sample sizes were
chosen to be towards the larger end of the range used in
previously published studies of effects of TRP-rich proteins
on amino acids, cognition and/or emotion, i.e. from N=14 to
N=23 per group (Markus et al. 2008, 2010; Merens et al.
2005; Scrutton et al. 2007). Cognitive and emotional function,
mood and physical sensations were assessed at baseline
(screening day) and between 60 and 180 min after supplement
consumption on the test day. The between-subjects design
reduces practice effects as well as order effects that may result
from differential tolerance, etc., when using within-subject
designs in multiple dose treatment studies.
Treatment
Active condition LumiVida™ (DSM Nutritional Products
Ltd., Kaiseraugst, Switzerland) is a hydrolysed, enzymatic
digest of a dietary egg-white protein manufactured by using
a proprietary mix of enzymes from a dietary source to provide
a high-quality source of peptides. LumiVida™ contains a
guaranteed minimum quantity of bioactive TRP-containing
peptides. The molar ratio of these TRP peptides to peptides
containing the LNAAs valine, isoleucine, leucine, tyrosine
and phenylalanine is approximately 0.2. LumiVida™ is
intended for use in food products such as beverages, bars,
yoghurt drinks, etc., and these doses were considered (at the
time) to be (a) sufficiently active on TRP entry to the brain (b)
at a commercially viable level. In this study, LumiVida™ was
taken as a citrus-flavoured non-nutritively (Acesulfame)
sweetened beverage; 2 and 4 g of LumiVida™ were used,
which contain approximately 0.13 and 0.27 g TRP,
respectively.
Placebo condition Casein hydrolysate (3.11 g; primary milk
protein; DSMNutritional Products Ltd., Kaiseraugst, Switzer-
land) was used to provide an intermediate amount of energy
and total protein, in the placebo beverage, relative to the active
treatments. Casein hydrolysate is low in TRP and so will not
raise serotonin synthesis.
Both treatments were supplied in sachets of powder, ad-
ministered as suspensions in approximately 150-ml tap water.
Double-blind randomisation was carried out by means of a
label code associated with a specific participant ID number,
whose meaning was known only to the supplier. Participants
were allocated randomly to these numbers.
Participants
Participants were 60 women, aged 45 to 65, physically and
mentally healthy, as defined by a brief medical history check
(not concurrently receiving medical/pharmacological treat-
ment except mild painkillers), free of gastrointestinal com-
plaints, diabetes and cardiovascular disease, not in pain and
not diagnosed with a psychiatric disorder (no treatment for
depression or anxiety and other psychiatric disorders). Body
mass index was required to be above 18 and below 35.
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In addition, it was necessary to establish menstrual status
prior to arranging the first (baseline) visit, as any premeno-
pausal participants needed to be tested in the follicular phase
(within 2 weeks of the start of menstrual bleeding). Menstrual
status was established by questionnaire once verbal consent
was established.
Recruitment was via notices in local newspaper/magazines,
women’s organisations, campus posters, e-mail announce-
ments and word of mouth (not family members). A participant
information sheet was sent or read out to participants initially
expressing interest, and if this seemed acceptable (verbal
consent), they were invited for a screening interview and
baseline test morning. The following restrictions applied: (i)
No alcohol on the day before testing (including baseline day),
(ii) usual caffeinated drink (if taken) to be drunk before
0800 hours on each test day and (iii) no other food or drink
except water to be taken from 2200 hours the previous eve-
ning, until after testing has ended.
The study was approved by the University Ethics Commit-
tee of the University of Roehampton, in accordance with the
1964 Declaration of Helsinki. All participants gave informed
signed consent before participating in the study.
Procedure
Prior to the baseline test, participants were sent four brief
questionnaires to assess personality characteristics that have
been associated with serotonin function: Dutch Personality
Inventory—Neuroticism scale (21 items), translated into En-
glish by a native Dutch speaker and refined by a native
English speaker (Luteijn et al. 1975); this questionnaire has
been used in previous studies of dietary manipulation of
serotonin (Markus et al. 1998, 2010); Depression Anxiety
and Stress Scale (DASS; 21 items, 1-week retrospective;
Antony et al. 1998); Aggression Questionnaire—short form
(Bryant and Smith 2001); Barratt Impulsiveness Scale—15-
item short form (Spinella 2007).
Schedule of testing is given in Table 1: participants arrived
at the laboratory between 0830 and 0850 hours. At the screen-
ing interview, the information about the study was repeated,
and they were asked to read and sign the consent form, a copy
of which they kept. Then, the brief health history and demo-
graphic information was checked, which was followed by
measurements of their height and weight. Next, the participant
was offered water to drink, and then asked to complete a series
of 28 mental and physical sensation ratings on a computer
screen. This computer-based mental and physical sensations
scale (MAPSS) was run on E-Prime (v.2, Psychology Soft-
ware Tools, Inc., PA, USA), questions were randomly se-
quenced and the scale ranged from 1 = 'Not at all' to 9 =
'Extremely'. This test was repeated once again at the end of all
testing. MAPSS has been found to be sensitive to mood
changes following psycho-pharmacological manipulations
(Rogers et al. 2010).
Participants then completed the national adult reading test
(NART; 2nd edition, Windsor NFER-Nelson, 1991), which
provides a measure of stable verbal IQ and was only given on
the baseline test day. This involves participants reading aloud
a series of 50 words, presented one by one on cards: they were
scored for number of errors in pronunciation. After a rest of
approximately 1 h, the baseline set of cognitive tests started at
1030 hours, in line with the subsequent test day, and lasted 2 h
and 20 min including breaks.
Treatment test session
As before, participants arrived in the laboratory for 0830–
0850 hours and were asked about their current health, in case
any adverse events needed to be noted, and also whether they
experienced any stress so far that morning. The test schedule
followed that of the baseline day, except that (i) two blood
samples were drawn during the morning using a butterfly
needle inserted in a vein in the antecubital fossa of the forearm
and (ii) the freshly prepared experimental drink was given
immediately after the first MAPSS, followed by a 1-h rest
before cognitive testing began. Just prior to the first test
(reaction time), a buccal (cheek) cell swab was taken, for later
DNA assay (data not presented here). The first blood sample
in the morning was drawn in a seated position prior to the
initial MAPSS ratings, while the second sample was drawn
Table 1 Cognitive test battery schedule
Time Task
09:20 Mental and physical sensations scale (MAPSS)
09:25 National adult reading test (or drink on treatment test day)
09:30 Rest 1 h
10:30 Simple reaction time
10:40 Rotary pursuit task
10:55 Rest (or second blood sample of Day 2)
11:10 Verbal recognition memory (VRM); immediate recall/recognition
11:15 Match to sample (MTS): colour patterns for visual matching,
attention, motor skill and reaction times
11:20 Rest
11:35 VRM: free delayed recall: paper test
11:40 Rapid visual processing (RVP): number sequence pattern
detection
11:50 VRM: delayed recognition
11:55 Affective go/no-go (AGN): positive/negative/neutral target words
12:15 Emotional facial expression task: perception of angry, fearful, sad,
surprised, disgusted and happy expressions
12:25 Rest
12:30 Driving hazard perception task
12:50 MAPSS
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90 min later at the time of expected peak changes in plasma
TRP and TRP/LNAA levels (Mitchell et al. 2011), following
completion of the rotary pursuit task but before starting the
critical memory tests. This blood sample was taken in order to
verify that the LumiVida™ treatment raised the plasma TRP/
LNAA amino acid ratio in the expected dose-dependent man-
ner, compared with the control. The blood (6 ml) was collect-
ed in a Vacutainer™ lithium-heparin tube, shaken, stored on
ice and processed within 2 h in the Clinical Laboratory at the
University of Roehampton (see ‘Blood assays’ below). After
cognitive testing ended, participants completed a ‘Tolerabili-
ty’ questionnaire to assess any symptoms they may have
experienced and were asked whether they believed they had
been given a placebo or active treatment drink. Then, partic-
ipants were debriefed, given a £60 store voucher card, reim-
bursed travel expenses up to £10 and offered free lunch in the
university canteen.
Test battery details
Considering space restrictions, detailed test information is
only given for those tests that produced significant results.
Performance on the following cognitive tests did not show
statistically reliable treatment effects: simple and
sustained reaction time (Rogers et al. 2010), rotary pursuit
task (model 30014A, Lafayette Instruments), verbal rec-
ognition memory, match to sample visual search, rapid
visual information processing (the latter three are from
CANTABeclipse v3, Cambridge Cognition Ltd.; http://
www.camcog.com/cantab-tests.asp) and the driver hazard
perception test (from the driving theory test, professional
version 2008–2009, Oasis Software Ltd.). Further
information about these tasks is available from the
manufacturers and on request from the authors.
Affective go/no-go task (AGN; CANTABeclipse v3)
This test assesses information processing biases for pos-
itive and negative stimuli (Cambridge Cognition Ltd.;
http://www.camcog.com/cantab-tests.asp). The test
consists of several trial blocks, each of which presents
a series of words from two of three different affective
categories: positive (for example, joyful), negative (for
example, hopeless) and neutral (for example, element).
The participant is given a target category and is asked to
press the response pad only when they see a word
matching this category. Some pairs of trials maintain
the same target type (non-shift; easier), whereas others
change the target type (shift; harder). Outcomes are
category-specific reaction times, their differences and
accuracy.
Facial emotion recognition task
This task assesses subjective perception of positive and neg-
ative social stimuli, i.e. facial expressions of six basic
emotions, fear, anger, sadness, happiness, surprise and
disgust. The version used here is adapted from Richards
et al. (2002). The task is run on a computer using E-Prime
(v.2, Psychology Software Tools, Inc., PA, USA) and presents
participants with black and white images of a male face, front
on, one face at a time (from the Ekman face set, Ekman and
Friesen 1978). The expressions on the face are arrayed in
blends of two emotions varying in ratios of 10 %:90 %,
30 %:70 %, 50 %:50 %, 70 %:30 % and 90 %:10 %. Partic-
ipants are asked to rate each face for the intensity of one of the
emotions, on a 9-point scale from 1 = ‘not at all (emotion)’ to 9
= ‘very (emotion)’. Each emotion is blended separately with
two others in this way, thus providing an average rating of
perceived emotional intensity over ten faces of varying
blends. However, the rated response to the two 50 % blends
for each emotion (e.g. fear with sadness and surprise) should
provide the most reliable measure of perceptual bias, so these
were analysed separately.
Blood assays
Blood samples were centrifuged in Vacutainer™ lithium-
heparin tubes at 4,000 rpm for 10 min at 4 °C. Then, 750 μl
plasma supernatant was pipetted into each of two Eppendorf
cups. These had been prepared with 120 μl 25 % (w/v)
solution of sulfosalisylic acid, to deproteinise the plasma.
The mixture was vortexed for 1 min until evenly milky, then
frozen at −80 °C prior to transportation for assay. The amino
acid assays were carried out by DSM Food Specialties B.V.,
Delft, NL. Plasma amino acid analysis was conducted with
HPLC via a 2- to 3-mm Bischof Spherisorb ODS II column.
The plasma TRP ratio was calculated by dividing the plasma
TRP concentration by the sum of the other LNAA, i.e. valine,
isoleucine, leucine, tyrosine and phenylalanine. All amino
acid ratios are presented as molar weight ratios.
Data analyses
The hypotheses were tested by comparing dependent variable
means for significant differences between treatment groups on
the treatment test day (Day 2), after adjusting for baseline
performance (Day 1). This was achieved using analysis of
covariance (ANCOVA) including Day 1 performance as a
covariate. In addition, for the reading-dependent AGN test,
errors on the NART (a measure of English verbal IQ) were
included as a covariate. This variable did not differ by treat-
ment group (see Table 2) but could still contribute to variance
in performance because NARTerrors correlate positively with
increased latency to respond and more omission errors in this
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task (e.g. Spearman’s rho=0.30–0.50). These ANCOVAs also
included planned contrasts between each LumiVida™ dose
group and the control group (simple contrasts). Baseline
means were compared by one-way ANOVAs or Kruskal–
Wallis tests for non-parametric data. Where data were skewed
greater than ±1, each variable was transformed appropriately,
e.g. positive skew reduced by natural log (Ln) transformation,
before analysis. Significance level (alpha) was taken as 0.05:
where results were predicted by directional hypotheses, one-
tailed probability (p) levels are reported; otherwise, two-tailed
levels are given. Significance of multiple pairwise compari-
sons within a particular dependent variable was adjusted by
Bonferroni correction or by use of Dunnett’s t test. Otherwise,
alpha was not adjusted for numbers of tests of a priori hypoth-
eses across multiple variables, as that would increase the risk
of Type II errors, particularly for relatively small sample sizes.
Results
Participant characteristics
Sixty women aged 45–65 years completed the study, 19
receiving the control treatment, 20 receiving 2 g LumiVida™
and 21 receiving 4 g LumiVida™. Their average age was 55.0
(SD=6.1) years and as randomisation to group was stratified
by age, treatment groups did not differ by age (Table 2, F(2,
57)<1). The groups also did not differ significantly by NART
errors (verbal IQ estimate) (Table 2, F(2, 57)=1.82). There
were also no differences in impulsivity or DASS-21 scores
(depression, anxiety and stress) between groups (data not
shown). In partial correlations controlling for body weight,
these traits were not significantly related to baseline TRP/
LNAA ratio, with the exception of impulsivity which was
weakly negatively correlated (r(44)=−0.27, p<0.05, one tail),
in those participants able to give blood samples. However,
despite double-blind randomisation, the 2-g LumiVida™
group was significantly lower in neuroticism (Dutch person-
ality inventory) and total aggression (12-item aggression
questionnaire) compared with the control group, F(2, 57)=
3.34 and 3.46, respectively, both p<0.05 (Table 2). Thus, for
mood and emotional processing tasks, these traits were exam-
ined for significant influence on the outcomes by ANCOVA.
Participants did not differ significantly in BMI across
groups, with BMI ranging from 17.7 to 34.3 (mean (SD)=
24.9 (3.3)). Fifty-five per cent of participants had never
smoked; the remainder being ex-smokers, although four par-
ticipants admitted to occasionally having a ‘social’ cigarette.
Plasma TRP and TRP/LNAA ratio
Blood assays
Given the collection difficulties, no blood was obtainable
from 13 participants: three of the control, six of the 2-g
LumiVida™ dose and four of the 4-g LumiVida™ dose. In
addition, the second blood sample was not available for two
participants from the 4-g LumiVida™ dose. Samples were
assayed in duplicate: intra-assay coefficients of variation for
TRP were 5.1 % for sample 1 (baseline) and 4.6 % for sample
2 (treatment test day), indicating highly reliable assay data.
For three cases, results were only available from one sample
(two cases for sample 1; one for sample 2). Distributions were
normal.
Effects on plasma tryptophan
Plasma TRP pre- and posttreatment levels (samples 1 and 2)
are given in Table 3. The baseline levels (sample 1) did not
differ between treatment groups, one-way ANOVA group
effect, F(2, 44)=1.02, variance explained ηp
2=0.04, NS.
The impact of treatment condition on any change in plasma
TRP was examined using one-way ANCOVA on the second
TRP sample level, with sample 1 TRP levels as the covariate,
i.e. testing for the group effect adjusted for any influence of
baseline levels. Treatment had a highly significant effect on
plasma TRP, ANCOVA group effect, F(2, 41)=50.2,
p<0.001, ηp
2=0.71. Baseline (sample 1) TRP levels were a
strongly significant covariate, F(1, 41)=63.4, p<0.001, ηp
2=
0.61 (see Table 3). Compared with the control, TRP levels
were significantly higher after both 2 and 4 g LumiVida™,
and higher after 4 g than after 2 g, Bonferroni-adjusted
pairwise comparisons, all p<0.001 (Fig. 1).
Within each condition, sample 2 TRP levels were increased
compared with sample 1 for both 2 g and 4 g treatments,
paired t(13)=3.52, p<0.01, t(14)=9.80, p<0.001, respective-
ly. Conversely, TRP levels for sample 2 were less than for
Table 2 Age, NART errors, neuroticism and aggression by treatment group
Treatment group Number Age (years) mean (SD) NART errors mean (SD) Neuroticism mean (SD) Aggression mean (SD)
Control 19 55.7 (6.1) 9.3 (4.7) 11.4 (8.5) 15.7 (6.3)
2 g LumiVida™ 20 54.6 (5.5) 8.4 (5.3) 6.3* (4.5) 11.8* (2.7)
4 g LumiVida™ 21 54.7 (6.9) 11.5 (6.1) 8.1 (5.5) 15.5 (6.1)
*p<0.05, mean different from control; Dunnett’s t for multiple comparison to the control group
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sample 1, following the control treatment, paired t(15)=2.86,
p<0.02 (Fig. 1). These differences between effects of treat-
ments are supported by a significant Condition×sample inter-
action, RMANOVA F(2, 42)=51.4, p<0.001.
Effects on plasma TRP/LNAA ratio
Plasma TRP/LNAA pre- and posttreatment ratios (samples 1
and 2) are given in Table 4. The baseline ratio (sample 1) did
not differ between treatment groups, one-way ANOVA group
effect, F(2, 44)<1, variance explained ηp
2=0.004, NS.
The impact of treatment condition on any change in plasma
TRP/LNAA ratio was examined using one-way ANCOVA on
the sample 2 (posttreatment) TRP/LNAA ratios, with sample
1 TRP/LNAA ratios as the covariate, i.e. testing for the group
effect adjusted for any influence of baseline ratios. Treatment
had a highly significant effect on plasma TRP/LNAA,
ANCOVA group effect, F(2, 41)=46.7, p<0.001, ηp
2=0.70.
Baseline (sample 1) TRP/LNAA ratios were a strongly sig-
nificant covariate, F(1, 41)=42.4, p<0.001, ηp
2=0.51 (see
Table 4). Compared with the control, TRP/LNAA ratios were
higher after both 2 and 4 g LumiVida™, and higher after 4 g
than after 2 g, Bonferroni-adjusted pairwise comparisons,
control vs. 2 and 4 g, p<0.001, 2 g vs. 4 g, p=0.002 (Fig. 2).
Within each condition, sample 2 TRP/LNAA ratios were
increased compared with sample 1 for both 2 and 4 g treat-
ments, paired t(13)=8.18, p<0.001, t(14)=7.58, p<0.001,
respectively: these increases in TRP/LNAA ratios
corresponded to 25 and 48 % increases over baseline, respec-
tively. Conversely, TRP/LNAA ratios for sample 2 were less
than for sample 1 following the control intervention, paired
t(15)=4.44, p<0.001, corresponding to a 9 % reduction from
baseline (Fig. 2). These differences between effects of treat-
ments are supported by a significant condition × sample
interaction, RMANOVA F(2, 42)=48.5, p<0.001.
Mental and physical sensations
Data reduction for mental and physical sensations
The recommended approach to analysing the 28 measures of
MAPSS is first to reduce the number of measures to a smaller
number of latent variables or factors using principal compo-
nent analysis (PCA) (Rogers et al. 2010). The PCAwas run on
all measures of MAPSS, treating each time point as a separate
case, in order to have enough cases (n=240) relative to vari-
ables tomake PCA reliable, and to allow testing for changes in
the same latent variables over repeated sessions. Although this
approach ignores the possibility that treatment conditions
could contribute to within-subject variance across measure-
ments, it is a common procedure in the literature, and using the
alternative multilevel approach on our large variable to sample
ratio presents additional problems of reliability (Reise et al.
2005). The initial solution, with varimax rotation, produced
seven components with Eigen values of >1; however, obser-
vation of scree plot and factor loadings suggested that a five-
factor solution would be a better fit, explaining 55 % of the
variance in total.
The first two factors were the dominant components
(Eigen=7.5, 3.5; %variance=13.9, 13.5, respectively). For
each factor, combined variables were computed by averaging
scores from all items that loaded >0.50, thus avoiding any
Table 3 Plasma TRP (μmol/g)
for samples 1 (pretreatment) and 2
(posttreatment)
Adj. mean means adjusted for
sample 1 levels
Treatment Sample 1 Sample 2
Mean SD Number Mean SD Number Adj.
mean
SD
Control 34.45 5.00 16 32.37 4.90 16 33.39 4.80
2 g LumiVida™ 37.18 6.77 14 41.80 6.26 14 40.12 4.83
4 g LumiVida™ 34.58 5.80 17 50.00 10.36 15 50.48 4.78
Total 35.31 5.86 47 41.18 10.43 45
Fig. 1 Effects of treatments on plasma TRP. Different letters indicate
differences between treatment groups, adjusted for baseline levels. With-
in-group pre- vs. posttreatment comparisons: sample 2 differed from
sample 1, *p<0.02; **p<0.01; ***p<0.001
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items that had lower loadings on more than one factor. Thus,
the first factor consisted of the following seven items, in order
of loading: ‘relaxed/calm/at ease’, ‘able to concentrate/focus’,
‘mentally alert/attentive/observant’, ‘cheerful/happy/content-
ed’, ‘clear-headed’, tranquil/peaceful’ and ‘energetic/active/
strong/lively’. This factor was labelled ‘wellbeing’ (overall
mean=6.71).
The second factor consisted of six items, in order of load-
ing: ‘muzzy/dazed/spaced out’, ‘fatigued/exhausted/worn
out’, ‘strange/weird/not my usual self’, ‘sleepy/drowsy/half
awake’, ‘headaches/feel headachy’ and ‘fidgety/twitchy’. This
factor was labelled ‘fatigue’ (overall mean=1.94).
The third factor consisted of four items (11.3 % of vari-
ance): ‘panicky/frantic’, ‘uneasy/apprehensive/concerned’,
‘fearful/scared/afraid’ and ‘anxious/worried/nervous’. This
factor was labelled ‘anxiety’ (overall mean=2.24).
The fourth factor consisted of six items (11.2 % of vari-
ance): ‘mind is racing’, heart is pounding/racing’, ‘buzzing/
feel stimulated/hyper’, ‘agitated/restless/jumpy’, ‘impulsive/
spontaneous’ and ‘tense/on edge’. This factor was provision-
ally labelled ‘agitation’ (overall mean=1.32).
The fifth factor consisted of just two items (5.1 % of
variance): ‘miserable/depressed/dejected’ and ‘hot/sweaty’.
This factor was labelled ‘negative affect’ (overall mean=
1.34).
In addition, to check that this PCA result had not been
substantially distorted by treatment effects, we also ran the
PCA in the same way on the first baseline MAPSS measure
only. Although this is not a reliable PCA given the large
variable to sample ratio, nevertheless, the factor loading was
very similar. The minor differences were that (a) two items,
‘fatigued’ and ‘headaches’, loaded weakly and negatively on
the wellbeing factor (−0.50 and −0.57, respectively) rather
than on the fatigue factor, while ‘strange’ did not load above
0.50 on any factor. (b) The agitation factor had a slightly
higher Eigen value than the anxiety factor, but the structures
were the same. Thus, it seems unlikely that treatment consid-
erations in later mood measures had significantly distorted the
factor loadings.
Effects on wellbeing
Wellbeing raw scores were normally distributed and did not
require transformation. Average wellbeing scores at baseline
(before intervention drink on the treatment test day) and
posttest are shown in Fig. 3. The baseline levels did not differ
between treatment groups, one-way ANOVA group effect,
F(2, 57)<1, variance explained ηp
2=0.03, NS.
The impact of treatment condition on any change in
wellbeing was examined using one-way ANCOVA on the
posttest, and posttreatment, wellbeing level, with baseline
levels as the covariate, i.e. testing for the group effect adjusted
for any influence of baseline levels. Treatment condition had a
significant though weak effect on wellbeing overall,
ANCOVA group effect, F(2, 56)=2.65, p<0.05 one tail,
ηp
2=0.09 (adjusted means (SD): control=6.32 (1.10); 2 g=
7.11 (1.11); 4 g=6.54 (1.10)). Baseline wellbeing levels were
a strongly significant covariate, F(1, 56)=33.02, p<0.001,
ηp
2=0.37. Compared with the control treatment, wellbeing
levels remained significantly higher after 2 g (Bonferroni-
adjusted pairwise comparisons, p<0.05, one tail) but not after
4 g LumiVida™. The difference in wellbeing between the two
dose groups was not significant. It can be seen in Fig. 3 that
wellbeing declined from baseline to posttest in the control and
Table 4 Plasma TRP/LNAA for
samples 1 (pretreatment) and 2
(posttreatment)
Adj. mean means adjusted for
sample 1 ratios
Treatment Sample 1 Sample 2
Mean SD Number Mean SD Number Adj. mean SD
Control 0.063 0.010 16 0.057 0.008 16 0.058 0.012
2 g LumiVida™ 0.064 0.007 14 0.080 0.008 14 0.080 0.011
4 g LumiVida™ 0.064 0.012 17 0.095 0.022 15 0.094 0.012
Total 0.064 0.010 47 0.077 0.022 45
Fig. 2 Effects of treatments on plasma TRP/LNAA ratios. Different
letters indicate differences between treatment groups, adjusted for base-
line ratios. Sample 2 differed from sample 1 within each treatment
condition, ***p<0.001
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(non-significantly) after 4 g LumiVida™ conditions but
remained stable after 2 g LumiVida™.
Posttest change from baseline was tested for significance
within each condition: posttest wellbeing levels were signifi-
cantly lower than baseline after the control treatment, paired
t(18)=3.30, p<0.01. However, neither the slight increase from
baseline after 2 g (t(19)=0.91) nor the decline after 4 g
LumiVida™ (t(20)=1.61) were statistically significant chang-
es from baseline. These differences between effects of treat-
ments on change from baseline are supported by a significant
condition×pre–post-interaction, RMANOVA F(2, 57)=3.53,
p<0.05, ηp
2=0.11. There was evidence for an average decline
in wellbeing from baseline to posttest, pre–post-main effect,
F(1, 57)=4.78, p<0.05, ηp
2=0.08 (see Fig. 3).
Effects on fatigue
Fatigue raw scores were positively skewed and so were Ln
transformed. Average fatigue (transformed) scores at baseline
and posttest are given in Table 5. The baseline levels did not
differ between treatment groups, one-way ANOVA group
effect, F(2, 57)<1, variance explained ηp
2=0.02, NS.
The impact of treatment condition on any change in fatigue
was examined using one-way ANCOVA on the posttest, and
posttreatment, fatigue level, with baseline levels as the covar-
iate, i.e. testing for group effect adjusted for any influence of
baseline levels. Treatment condition had a significant effect on
fatigue overall, ANCOVA group effect, F(2, 56)=4.42,
p<0.01, one tail, ηp
2=0.14 (see adjusted means, Table 5).
Baseline fatigue levels were a strongly significant covariate,
F(1, 56)=21.29, p<0.001, ηp
2=0.28. Compared with the
control treatment, fatigue levels remained low after 2 g
LumiVida™, by the end of testing (simple contrast, p<0.01,
one tail). Fatigue after 4 g LumiVida™ was intermediate but
not quite significantly different from the control (simple con-
trast, p=0.06, one tail). It can be seen in Fig. 4 that fatigue
increased from baseline to posttest in the control group and to
a lesser extent after 4 g LumiVida™ but remained stable and
low after 2 g LumiVida™.
Posttest change from baseline was tested for significance
within each condition: posttest fatigue levels were significant-
ly greater than baseline after the control treatment, paired
t(18)=3.13, p<0.01. However, the slight increase from base-
line after 4 g LumiVida™was not significant (t(20)=1.81, p=
0.09), and fatigue did not increase after 2 g LumiVida™,
t(19)=0.04, NS. These differences between effects of treat-
ments on change from baseline were supported by a signifi-
cant condition×pre–post-interaction, RMANOVA F(2, 57)=
3.39, p<0.05, ηp
2=0.11. There was evidence for an overall
increase in fatigue from baseline to posttest, pre–post-main
effect, F(1, 57)=9.76, p<0.01, ηp
2=0.15 (see Fig. 4).
Affective go/no go task
Specific data analyses issues
Dependent variables in this task include: latency to respond to
the target word; commission errors, when the key is wrongly
pressed to a distractor word; omission errors, when the key is
not pressed to a target word. Although the task outcomes can
be broken down into sub-trials varying in distractor valence,
for example, for the purposes of this report, the analyses are of
target valence only (positive or negative), i.e. neutral distractor
trials are combined with either positive or negative distractor
trials, depending on the target. One participant was unable to
complete the AGN task on Day 2, so she was excluded from
these analyses.
Effects on response latencies
It was predicted that participants would respond faster to
positive words with negative or neutral distractors after
LumiVida™ if the treatment reduced bias to negative stimuli.
For both doses, LumiVida™ reduced the latency to respond to
positive words, i.e. faster reactions, ANCOVA group effect,
F(2, 53)=3.05, p<0.03 one tail, ηp
2=0.10; contrasts, 2 g vs.
control, p<0.05, 4 g vs. control, p<0.05 (Fig. 5). This sug-
gests lessening of interference from negative or neutral
distractor words by the active treatment. Neither neuroticism
nor aggression scores were significant covariates.
Response latencies for negative target words were unaf-
fected by treatment condition (data not shown).
Fig. 3 Effects of treatments on wellbeing at baseline and posttest. The
significant pre–post by treatment interaction can be seen: 2 g LumiVida™
resisted any decline in wellbeing, and this effect was significantly differ-
ent from control. The effect of 4 g was closer to control but did not differ
significantly from either of the other groups. Different letters indicate
differences between treatment groups, adjusted for baseline levels. Only
in the control condition did the change (reduction) from baseline achieve
significance (see below), **p<0.01
Psychopharmacology (2014) 231:4595–4610 4603
Effects on errors of omission
These errors indicate failing to press the key in response to a
target word. It was predicted that LumiVida™ would reduce
such errors when the target was positive and distractors were
negative or neutral. Similarly to latency data, there was a
significant effect of treatment for the positive target condition;
moreover, neuroticism was a significant covariate for this
variable, F(1, 52)=6.10, p<0.02, ηp
2=0.11, and the resulting
adjusted main effect of treatment was strongly significant,
ANCOVA group effect, F(2, 52)=6.49, p<0.01, ηp
2=0.20.
Planned contrasts showed that this effect was due to a reduc-
tion in omissions after 2 g LumiVida™ vs. control, p<0.02,
but not after 4 g LumiVida™ vs. control, p>0.1 (Fig. 6). This
suggests that the presence of negative or neutral distractors
produced less interference in accuracy of responding to pos-
itive targets after the low dose of LumiVida™. There were no
significant effects of treatment on omission errors for negative
target words (F<1.62). There were also no effects of treatment
on errors of commission (i.e. incorrect key pressing to a
distractor word; F<1).
Facial emotional expression rating task
Specific approaches to data analysis
Following the ANCOVA including baseline day (Day 1)
performance as a covariate, comparisons between the control
and LumiVida™ groups were made using planned simple
effect contrasts. Post hoc comparisons between means for
the two doses of LumiVida™ were Bonferroni adjusted. The-
se analyses were performed on the overall average rating
including all ten blends of a given emotion, and separately
on ratings for faces with 50 % of a given emotion (averaged
over trials against two other emotions). In addition, for the
50 % blend data, one-sample t tests were used to test for mean
differences from the scale mid-point of 5, as a measure of
accuracy of emotional perception (significances indicated in
Fig. 7 and its legend). For this test, subjective ratings of
emotional intensities are the dependent variables, so age and
NART errors are not included as covariates; these latter vari-
ables did not differ by treatment. Neuroticism and aggression
Table 5 Effect of LumiVida™
on fatigue (Ln-transformed) for
baseline (pretreatment) and
posttesting on Day 2
Adj. mean means adjusted for
baseline levels
Treatment Baseline Posttest
Mean SD Number Mean SD Number Adj. mean SD
Control 0.51 0.51 19 0.91 0.68 19 0.85 0.48
2 g LumiVida™ 0.36 0.40 20 0.36 0.42 20 0.40 0.47
4 g LumiVida™ 0.40 0.36 21 0.59 0.53 21 0.61 0.47
Total 0.42 0.42 60 0.62 0.59 60
Fig. 4 Effects of treatments on fatigue during testing. Different letters
indicate differences between treatment groups, adjusted for baseline
levels. The significant pre–post by treatment interaction can be seen
(see text): 2 g LumiVida™ resisted any increase in fatigue, and this effect
was significantly different from the control, whereas the increase was
intermediate after 4 g. Posttest fatigue increased significantly from base-
line only after the control treatment, **p<0.01
Fig. 5 Effect of LumiVida™ on latencies to respond to positive target
words (with negative or neutral distractor words; all trials). Both doses of
LumiVida™ (hashed column=2 g; solid column=4 g) reduced the re-
sponse latency, *p<0.05 vs. control (open column). Means are adjusted
for baseline performance, age and NART errors
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scores were tested for significance of covarying: aggression
was never a significant covariate; neuroticism was significant
for anger and happiness, as described below. The dependent
variables and covariates reported here were not skewed, so
raw scores were analysed.
Effects on fear
Treatment condition significantly altered rated intensity of
expression of fear in 50 % blended faces, one-way ANCOVA,
F(2, 56)=5.40, p<0.01, ηp
2=0.162: rated fear was less after
2 g LumiVida™ vs. control (p<0.05), whereas ratings did not
differ between 4 g LumiVida™ and control (Fig. 7a). The
difference between LumiVida™ doses was significant,
p<0.01.
The results for the overall average fear rating were similar
(Table 6, there was a significant effect of treatment condition,
F(2, 56)=3.38, p<0.05, ηp
2=0.108, with less rated fear after
2 g LumiVida™ than after the control, although this effect was
not quite significant (p=0.055, one tail). Fear rating after this
dose was significantly less than after 4 g LumiVida™
(p<0.05), which did not differ from the control.
Effects on sadness
As with fear, treatment condition significantly altered rated
intensity of sadness in 50 % blended faces, one-way
ANCOVA, F(2, 56)=5.44, p<0.01, ηp
2=0.163: rated sadness
was less after 2 g LumiVida™ vs. control (p<0.05), whereas
ratings did not differ between 4 g LumiVida™ and the control
(Fig. 7b). The difference between LumiVida™ doses was
significant, p<0.01. For the overall average sadness rating,
there was no effect of treatment condition, F(2, 56)=1.45, NS,
ηp
2=0.049, and no difference between doses.
Effects on anger and surprise
There was no effect of treatment on anger ratings for 50 %
blended faces (F<1, ηp
2=0.022), nor on overall anger ratings
(F<1, ηp
2=0.00). Including neuroticism as a significant co-
variate (F(1, 55)=5.89, p<0.02) for the 50 % blended faces
ratings did not alter the results.
There was no effect of treatment on surprise ratings for
50 % blended faces, (F<1, NS, ηp
2=0.005), nor on overall
surprise ratings, (F(2, 56)=1.27, NS, ηp
2=0.043).
Effects on disgust
There was a weak effect of treatment condition on ratings of
disgust for 50 % blends, F(2, 56)=2.43, p<0.05 one tail, ηp
2=
0.080, with a slightly lower average rating after 2 g
LumiVida™ and higher rating after 4 g, although neither
group differed significantly from the control (Fig. 7c). There
was a trend for disgust to be rated lower after 2 g than after 4 g
LumiVida™ (p<0.10). For the overall average disgust rating,
there was no effect of treatment condition (F<1, ηp
2=0.026)
and no difference between doses.
Effects on happiness
There was a significant effect of treatment on ratings of
happiness for 50 % blends, when adjusted for the effect of
neuroticism as a significant covariate (F(1, 55)=4.97, p<0.05,
ηp
2=0.08), treatment effect, F(2, 55)=3.22, p<0.05, two tail,
ηp
2=0.11. There were no differences between the control and
either 2 or 4 g LumiVida™ but a higher rated perception of
happiness after 4 g compared with 2 g LumiVida™ (Fig. 7d:
p<0.05, two tail, Bonferroni corrected).
For the overall average happiness ratings, there was no
effect of treatment condition, F(2, 55)=2.11, NS, ηp
2=0.07),
and no difference between doses, when covarying for a sig-
nificant effect of neuroticism (F(1, 55)=5.03, p<0.05, ηp
2=
0.08), or when not.
Discussion
Effects of treatment on plasma TRP and TRP/LNAA
The expected dose-dependent increases in plasma TRP and
TRP/LNAA ratio were seen after active treatments: both 2 and
4 g LumiVida™ were effective in raising plasma levels of
TRP and the TRP/LNAA ratio, 90 min after administration.
The mean changes were 25 and 48 % above baseline, respec-
tively. These changes compare well with levels achieved by
Fig. 6 Effect of LumiVida™ on errors of omission for positive target
words (with negative or neutral distractor words; all trials). The lowest
dose (2 g) of LumiVida™ (hashed column) significantly reduced the
number of errors, *p<0.02 vs. control (open column); 4 g LumiVida™
(solid column) did not differ from the control. Means are adjusted for
baseline performance, age, NART errors and neuroticism. Data are natu-
ral log transformed to normalise positive skew
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studies using TRP-rich α-lactalbumin (Booij et al. 2006;
Merens et al. 2005), and also with pharmacokinetic data for
4 g LumiVida™ (Mitchell et al. 2011), and would be expected
to raise synthesis of serotonin in the brain; however, in a
previous report concerning LumiVida™, TRP levels and
mood, the dose that produced a substantial and lasting im-
provement in mood was at least 5-fold greater (Markus et al.
2008). It is also worth noting that the absolute doses of TRP
(0.08–0.16 g) are considerably smaller than typically used in
studies assessing effects of TRP alone (e.g. 0.5–7 g). More-
over, given that equivalent increases in TRP/LNAA after α-
lactalbumin are seen at doses containing about 0.5 g TRP, this
suggests that the LumiVida™ peptide preparation is substan-
tially more efficient in raising TRP/LNAA than α-
lactalbumin; the TRP/LNAA content ratio is at least double
that in α-lactalbumin, though it should be considered that
LumiVida™ might also provoke a greater insulin response,
thereby increasing peripheral uptake of competing LNAAs,
particularly the branched chain amino acids.
The control drink, containing 3.11 g casein hydrolysate,
slightly, but significantly, reduced TRP/LNAA relative to
baseline (9 %): this is to be expected given the increase in
Fig. 7 Effects of LumiVida™
treatments on perception of
particular emotions in faces with
50 % blends of those emotions: a
fear, b sadness, c disgust, and d
happiness. The mid-point of 5
(broken line) on the 1–9 scale
represents accurate perception of
50 % of the expression present
(by comparison with the other %
blends). Data are expressed as
mean ± SE for Day 2 ratings,
adjusted for baseline (Day 1).
Significant differences from mid-
point rating are indicated (one-
sample t tests), *p<0.05;
**p<0.01; ***p<0.001.
Differing letters (a and b) indicate
significant differences between
groups
Table 6 Effect of LumiVida™ on total ratings of emotional expressions: data are means (SE) over ten blends
Treatment group Number Fear Sadness Anger Disgust Surprise Happiness
Control 19 6.00a (0.20) 5.14 (0.22) 5.57 (0.16) 5.59 (0.25) 6.26 (0.16) 5.00 (0.16)
2 g LumiVida 20 5.55b (0.19) 5.19 (0.22) 5.56 (0.16) 5.39 (0.24) 5.92 (0.15) 4.84 (0.16)
4 g LumiVida 21 6.24a (0.19) 5.61 (0.21) 5.54 (0.15) 5.79(0.23) 5.99 (0.15) 5.21 (0.16)
Means adjusted for baseline. Differing lowercase letters (a and b) indicate differences between means for fear ratings; overall fear rating after 2 g
LumiVida™ was less than those for control (p<0.06) and 4 g LumiVida™ (p<0.05). No other emotion means differed on this measure
4606 Psychopharmacology (2014) 231:4595–4610
LNAA that would result from casein hydrolysate intake, al-
though there was no fasting comparison group in this study to
rule out a decline due to circadian changes.
Mental and physical sensations
Effects on mood, arousal and other physical sensations were
assessed using ratings made on a computer (Rogers et al.
2010), at baseline and after performance testing. Treatment
effects were found for the two dominant components, labelled
wellbeing and fatigue, following principal components
analysis.
Wellbeing tended to decline by the end of the testing
period. This decline was prevented specifically by 2 g
LumiVida™, though not by 4 g. One explanation for this
‘inverted-U’ dose–response effect could be that the higher
dose produced other effects that began to counteract any
improvement in wellbeing. In this respect, it is therefore
interesting that the effect on fatigue was also strongest for
the lower dose: 2 g LumiVida™ prevented any increase in
fatigue after testing, which was clearly apparent for the control
group, whereas 4 g had an intermediate effect. One study
using α-lactalbumin to raise TRP availability to the brain
reported increased nausea at a dose that produced less than
double the TRP/LNAA ratio to that seen here (Scrutton et al.
2007). Inverted-U-shaped responses have been reported in the
literature after TRP supplementation: α-lactalbumin supple-
mentation trials that increased plasma TRP/LNAA to 21–
67 % did not have an effect on mood (Booij et al. 2006;
Markus et al. 1998, 2000, 2008; Merens et al. 2005;
Scrutton et al. 2007). In a recent study comparing a higher
dose of egg-white protein hydrolysate (containing 0.8 g TRP)
against casein (providing a 10-fold difference in TRP/LNAA
content—not plasma—ratio), the egg-white protein hydroly-
sate induced an increase in feelings of vigour, whereas this
positive mood state declined after casein (Firk and Markus
2009). Conversely, a 15-fold increase in TRP/LNAA achieved
after an intravenous injection of 7 g pure TRP was shown to
impair mood and cognition (Sobczak et al. 2002a, 2003).
Thus, there may be an invertedU-shaped relationship between
TRP/LNAA ratios and mood in healthy subjects.
Nevertheless, adverse effects of TRP loading are more
usually seen at much higher doses (Silber and Schmitt
2010), and there is a previous report that an acute 12 g
LumiVida™ dose improves mood (Markus et al. 2008). Even
so, it should be noted that, in that study, participants were not
engaged in stressful performance testing, which itself can
affect mood as well as potentially the serotonin system
(Gibson and Green 2002; Robinson et al. 2010); indeed, stress
is known to upregulate the enzymes TRP pyrrolase and
indoleamine-2,3-dioxygenase involved in catabolysing TRP,
and thus potentially reducing its availability for brain seroto-
nin synthesis (Russo et al. 2003).
Anxiety was relatively low, though levels were slightly
higher before than after testing: treatment had no effect on
anxiety. The remainingmood states (agitation, negative affect)
were at low levels and were not affected by treatment.
These findings are most appropriately compared with pre-
vious research using healthy participants, as opposed to those
with a (family) history of affect disorders. Firstly, it is inter-
esting to note that the beneficial effects of 2 g LumiVida™ on
wellbeing are echoed by that dose’s prevention of fatigue
caused by the testing. As the wellbeing measure included
terms related to arousal and alertness, both mood effects might
reflect a slight underlying stimulant effect of 2 g LumiVida™.
Although some other studies have reported positive effects on
mood after TRP manipulation, these often involved substan-
tially higher doses of TRP and thus greater changes in TRP/
LNAA (Charney et al. 1982). Moreover, it is not clear to what
extent those improvements might reflect anxiolytic and even
sedative effects, which are often observed at higher TRP doses
(Fernstrom 2012; Leathwood and Pollet 1982; Sobczak et al.
2003). There are also several studies that have failed to find
reliable mood changes by TRP supplementation (Merens et al.
2005; Scrutton et al. 2007), though others have demonstrated
benefits to mood interacting with social behaviour context
(Young 2013). Observed effects may depend on the variety
of mood measures that have been used; the MAPSS measure
used here might be particularly sensitive in the context of this
study, but there are no previous reports of effects of TRP or 5-
HT changes on this measure.
Emotional processing and sensitivity
There is an expanding literature examining effects of seroto-
nin manipulations on aspects of emotional processing; the
interest arises from attempts to understand the role of seroto-
nin in affect disorders such as depression and anxiety (Cowen
2008; Robinson et al. 2010; Robinson and Sahakian 2009).
However, there are fewer studies that have looked at TRP
supplementation on such effects in healthy participants. The
theory is that in states of low serotonin activity, such as in
depression, there is an attentional bias toward negative stimuli
(Harmer 2008; Mathews and MacLeod 2005). Therefore,
emotional processing is assessed by comparing responses to
negative vs. positive stimuli; for example, speed and accuracy
of recognition of pleasant and unpleasant emotional expres-
sions or responses to target vs. distractor emotional words
(Mathews and MacLeod 2005).
However, the results have not been entirely consistent; one
oral dose of 1.8 g TRP enhanced recognition of both happy
and fearful faces (Attenburrow et al. 2003), whereas 3 g/day
TRP for 14 days increased recognition of happiness but de-
creased recognition of disgust expressions, and reduced atten-
tion to negative stimuli, suggesting a shift in bias toward
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positive stimuli (Murphy et al. 2006). Such effects are more
often seen in women than men (Murphy et al. 2006).
In this study, LumiVida™ produced faster and more accu-
rate (fewer omissions) responding to positive target words,
which might reflect less distraction by, and thus a shift in
attention from, negative words, as well as increased attention
to positive words. It is notable that the most reliable effect was
again for the 2 g dose—only this dose improved accuracy,
although both doses were equally effective in reducing the
latency to respond. Moreover, in the test of perception of
emotional expressions, 2 g was again the effective dose,
producing reductions in, and increased accuracy of, ratings
of fear and sadness: one exception was a slightly more accu-
rate perception of 50 % happy expressions after 4 vs. 2 g
LumiVida™. These findings are consistent with LumiVida™
increasing serotoninergic activity in pathways processing
emotional stimuli, leading to a potential anti-depressant like
activity of a shift in emotional processing away from negative
bias (Bari et al. 2010). Importantly, we controlled for any
influence of neuroticism here, as such a ‘threat sensitivity’
aspect of personality has been shown to interact with seroto-
ninergic modulation of brain processing of emotional expres-
sions (Cools et al. 2005). It is worth emphasising that, al-
though the group receiving the effective 2 g dose was also the
least neurotic and aggressive of the three groups, these per-
sonality differences were adjusted for by analysis of covari-
ance, and either had no impact, or, if anything, strengthened
the effect of that dose. This argues against personality differ-
ences contributing to the lack of linear dose-response results,
but given the relevance of these traits to serotonin function, the
possibility of residual confounding must be acknowledged.
Summary
Consistent with accumulating evidence from both en-
hancement and depletion of serotonin function (Murphy
et al. 2006; Robinson and Sahakian 2009; Silber and
Schmitt 2010), the most reliable effects of LumiVida™
across the tasks have been on processing of emotionally
relevant stimuli. The direction of these effects is in line
with the widely acknowledged antidepressant function of
enhanced serotonin neurotransmission, i.e. a shift in pro-
cessing bias from negative towards positive stimuli (Bari
et al. 2010; Sharp and Cowen 2011).
One limitation of this study was restriction of participants
to middle-aged women, who may be more susceptible to
dietary TRP manipulation than men (Murphy et al. 2006;
Silber and Schmitt 2010). Moreover, there was no fasted-
only condition, i.e. all comparisons are made to a casein
hydrolysate control treatment, which, while matching for en-
ergy and protein intake, may not be inert itself on the behav-
iours considered here. Nevertheless, it is possible that
comparison with a fasted group may have exaggerated bene-
ficial effects of LumiVida™. Still, the lack of linear dose-
response results in this study questions whether the mecha-
nism of action is the hypothesised increased release of sero-
tonin per se. The pattern of results could depend on individual
differences in susceptibility of brain serotonin function to
dietary manipulation, although this was not indicated by the
personality measures examined here. A possible role for se-
rotonin transporter receptor gene polymorphisms remains to
be explored in our data.
In conclusion, firstly our data provide the evidence that
consumption of LumiVida™ does not induce any negative
effects. Furthermore, these findings encourage the conclusion
that daily consumption of a low dose of LumiVida™ may
have beneficial effects on emotional function that may pro-
mote feelings of wellbeing; however, further work with such
chronic dosing is required to be confident of this. These acute
results suggest the potential for some emotional benefits,
particularly during demanding occasions, and thus could con-
fer resistance to depressive episodes.
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